Hot High Tech Stocks For 2019

My Top Pick for speculative investors for 2017 is the company that operates the most popular Internet search engine in the largest Internet market in the world, explains global expert Paul Goodwin, editor of Cabot Emerging Markets Investor.

Baidu (BIDU) is the choice of most of the nearly 700 million Chinese who go online every month. The company’s success springs from the accuracy and ease of use of its Chinese-language search engine.

BIDU ran into trouble in 2011 and 2012, as it lost out to more nimble competitors during the massive Chinese switchover to mobile devices as the primary way to access the internet.

But BIDU soared from $83 in March 2015 to $252 in November 2014, its all-time high. Since that high, BIDU has been up and down, but has traded in a steadily tightening range.

The result is a stock with a bargain basement 11 P/E and a huge capital spending program that is moving the company into mobile payments, online marketplaces and performance-based online market services.

Hot High Tech Stocks For 2019: Interactive Intelligence Inc.(ININ)

Advisors’ Opinion:

  • [By Lisa Levin]

    Interactive Intelligence Group Inc (NASDAQ: ININ) shares were also up, gaining 18 percent to $28.06 after the company reported stronger-than-expected quarterly results.

Hot High Tech Stocks For 2019: H&E Equipment Services Inc.(HEES)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of United Rentalsgiving a similar performance but alsopulling away fromsmall cap peer H&E Equipment Services, Inc (NASDAQ: HEES):

  • [By Peter Graham]

    A long term performance chart shows shares of United Rentalsgiving a similar performance and pulling away fromsmall cap peer H&E Equipment Services, Inc (NASDAQ: HEES):

Hot High Tech Stocks For 2019: Ford Motor Company(F)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    Car dealers often carry the financial consequences of decisions manufacturers make about model line, model distribution, and model survival. Among the best examples of this is when GM (NYSE: GM) shuttered Pontiac, Hummer, Oldsmobile, and Saturn almost 15 years ago as the largest car company struggled to survive. Ford (NYSE: F) is in a related struggle, although not life threatening. It will kill the Taurus, Fusion, C-Max, and Fiesta. Some of its dealers will be left with only two car brands– the Mustang and new Focus Active

  • [By Paul Ausick]

    Ford Motor Co. (NYSE: F) sold 77,895 F-Series pickups in June, topping sales of General Motors Co.’s (NYSE: GM) Chevy Silverado by 27,380 units. Adding in sales of the GMC Sierra, Ford outsold GM in the pickup wars by 11,637 units.

  • [By Ezra Schwarzbaum]

    Ford Motor Company (NYSE: F) announced Sunday night its CEO Mark Fields will be replaced by Jim Hackett, the president of Ford Smart Mobility LLC.

    The unexpected move comes not long after the company’s annual shareholder meeting, held virtually on May 11.

Hot High Tech Stocks For 2019: Steelcase Inc.(SCS)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Steelcase Inc. (NYSE: SCS) was raised to Strong Buy from Market Perform at Raymond James.

    SUPERVALU Inc. (NYSE: SVU) was raised to Outperform from Sector Perform at RBC Capital Markets. Shares were indicated up 6% at $3.54 on Thursday.

  • [By Lisa Levin]

    Steelcase Inc. (NYSE: SCS) shares shot up 5 percent to $15 as the company reported better-than-expected results for its second quarter.

    Shares of Nabriva Therapeutics plc (NASDAQ: NBRV) got a boost, shooting up 10 percent to $9.71. Nabriva Therapeutics announced a $80 million common stock offering.

  • [By Money Morning Staff Reports]

    These changes all emanate from the Ford Smart Mobility unit. Who ran that unit? New incoming Ford CEO Jim Hackett. Before joining Ford Mobility, Hackett was the corporate CEO of Steelcase Inc. (NYSE: SCS), where he transformed the company from a humdrum maker of desks to a designer of flexible, output-enhancing workspaces.

  • [By Lisa Levin]

    Steelcase Inc. (NYSE: SCS) shares dropped 14 percent to $14.10 after the company reported downbeat earnings for its first quarter and issued a weak outlook for the second quarter.

Hot High Tech Stocks For 2019: Dermira, Inc.(DERM)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Novo A’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Novo+A

    These are the top 5 holdings of Novo AInogen Inc (INGN) – 3,549,320 shares, 59.83% of the total portfolio. Acceleron Pharma Inc (XLRN) – 1,553,937 shares, 9.34% of the total portfolio. Dermira Inc (DERM) – 1,984,364 shares, 7.81% of the total portfolio. Shares added by 3.27%Corvus Pharmaceuticals Inc (CRVS) – 3,244,046 shares, 4.76% of the total portfolio. Akebia Therapeutics Inc (AKBA) – 2,225,000 shares, 4

  • [By Paul Ausick]

    Dermira Inc. (NASDAQ: DERM) traded down about 64% Monday and posted a new 52-week low of $8.95 after closing Friday at $25.16. The stock’s 52-week high is $38.39. Volume was about 40 times the daily average of around 615,000 shares. The company’s trial of a new acne treatment failed to meet the designated endpoints.

  • [By Ben Levisohn]

    Current market dynamics, particularly in the SMID biotech universe, provide a plethora of opportunities for the company to augment the breadth and depth its pipeline in its core therapeutic areas, including neurology, ophthalmology and dermatology, where innovation is rife and where consolidation of some of the smaller players in the space is likely, in our view. Stocks in our SMID coverage universe that could potentially constitute future acquisition targets forAllergan include Aclaris Therapeutics (ACRS) and Dermira (DERM) (both have mid- to late-stage dermatology assets in development). We note with interest the collaboration with Heptares announced yesterday evening for the development of several M1, M4 and dual M1/M4 agonists in development for a variety of neurological diseases, including Alzheimers disease. Notwithstanding this above, larger scale transactions of course cannot be ruled out, and we note todays market commentary (Fox Business) regarding the potential sale of Valeant Pharmaceuticals International’s (VRX) Bausch & Lomb unit. It is reasonable to assume thatAllergan could be a bidder for this asset, given the companys presence in ophthalmology, as well as CEO Brent Saunders familiarity with the asset (he was the CEO prior to its sale toValeant in 2013 for $8.7bn). At the time of its sale to Valeant, B&L was generating c.$3bn in revenues and growing at a double-digit rate. Current sales of the asset are unclear due to the reporting structure of Valeant, as well as concerns regarding the companys operating/ pricing strategy.

  • [By Chris Lange]

    Dermira Inc. (NASDAQ: DERM) watched its shares absolutely collapse early on Monday after the firm reported disappointing results from its late-stage trials in patients with acne vulgaris. Essentially, Dermiras Phase 3 trials of the investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints.